The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of rituximab plus high-dose ara-C (HDAC)-containing chemotherapy (CTX) followed by ASCT in untreated mantle cell lymphoma (MCL): Japan Clinical Oncology Group study (JCOG0406).
 
Michinori Ogura
Honoraria - Eisai; Meiji Seika Kaisha; Takeda
Consulting or Advisory Role - Meiji Seika Kaisha; Mundipharma
Research Funding - Celgene (Inst); Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Mundipharma (Inst); Novartis (Inst); Pfizer (Inst); Solasia Pharma (Inst); Takeda (Inst)
 
Kensei Tobinai
Research Funding - Chugai Pharma (Inst); Zenyaku Kogyo (Inst)
 
Taro Shibata
No Relationships to Disclose
 
Kiyoshi Ando
Research Funding - Kyowa Hakko Kirin (Inst)
 
Mitsutoshi Kurosawa
No Relationships to Disclose
 
Hiroshi Gomyo
No Relationships to Disclose
 
Naokuni Uike
No Relationships to Disclose
 
Norifumi Tsukamoto
No Relationships to Disclose
 
Noriko Fukuhara
No Relationships to Disclose
 
Tatsu Shimoyama
No Relationships to Disclose
 
Masafumi Taniwaki
No Relationships to Disclose
 
Kisato Nosaka
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin
 
Yoshihiro Matsuno
No Relationships to Disclose
 
Tomomitsu Hotta
No Relationships to Disclose
 
Kunihiro Tsukasaki
Honoraria - Chugai Pharma; GlaxoSmithKline; Kyowa Hakko Kirin
Consulting or Advisory Role - SymBio Pharmaceuticals; Takeda
Research Funding - Chugai Pharma (Inst); Novartis (Inst); Pfizer (Inst)
 
Yasuo Morishima
No Relationships to Disclose
 
Kazuhito Yamamoto
Honoraria - Janssen; Kyowa Hakko Kirin; Novartis; Takeda
Consulting or Advisory Role - Kyowa Hakko Kirin; Novartis
Research Funding - ARIAD (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Zenyaku Kogyo (Inst)